UA96926C2 - Применение sdf-1 для лечения и/или профилактики неврологических заболеваний - Google Patents

Применение sdf-1 для лечения и/или профилактики неврологических заболеваний

Info

Publication number
UA96926C2
UA96926C2 UAA200802964A UAA200802964A UA96926C2 UA 96926 C2 UA96926 C2 UA 96926C2 UA A200802964 A UAA200802964 A UA A200802964A UA A200802964 A UAA200802964 A UA A200802964A UA 96926 C2 UA96926 C2 UA 96926C2
Authority
UA
Ukraine
Prior art keywords
sdf
prevention
treatment
neurological diseases
neurological
Prior art date
Application number
UAA200802964A
Other languages
English (en)
Ukrainian (uk)
Inventor
Урсула Бошерт
Аманда Праудфут
Линда Кади
Пьер Ален Витт
Жером Вожсик
Original Assignee
Мерк Сероно Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Сероно Са filed Critical Мерк Сероно Са
Publication of UA96926C2 publication Critical patent/UA96926C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается применения SDF-1 для лечения и/или профилактики неврологического заболевания.
UAA200802964A 2005-10-31 2006-10-30 Применение sdf-1 для лечения и/или профилактики неврологических заболеваний UA96926C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05110206 2005-10-31

Publications (1)

Publication Number Publication Date
UA96926C2 true UA96926C2 (ru) 2011-12-26

Family

ID=35967039

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200802964A UA96926C2 (ru) 2005-10-31 2006-10-30 Применение sdf-1 для лечения и/или профилактики неврологических заболеваний

Country Status (14)

Country Link
US (1) US20080253996A1 (ru)
EP (1) EP1942940A2 (ru)
JP (1) JP2009513689A (ru)
KR (1) KR20080060226A (ru)
CN (1) CN101300031A (ru)
AR (1) AR058173A1 (ru)
AU (1) AU2006310577B2 (ru)
BR (1) BRPI0617823A2 (ru)
CA (1) CA2617598A1 (ru)
EA (1) EA015716B1 (ru)
NZ (1) NZ565639A (ru)
UA (1) UA96926C2 (ru)
WO (1) WO2007051785A2 (ru)
ZA (1) ZA200800981B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9249204B2 (en) * 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
AU2012268078B2 (en) * 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
US11419916B2 (en) * 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
WO2014204795A1 (en) * 2013-06-19 2014-12-24 Merck Sharp & Dohme Corp. Assay for determining endogenous levels of analyte in vivo
JP6796060B2 (ja) * 2014-09-10 2020-12-02 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 画像レポート注釈同定
ITUA20161364A1 (it) 2016-03-04 2017-09-04 Antonino Cattaneo Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.
WO2018144817A1 (en) * 2017-02-03 2018-08-09 Vicapsys, Inc. Modified cxcl12 polypeptides and uses thereof
CN107325187B (zh) * 2017-07-19 2021-11-09 黄子为 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物
US11553871B2 (en) 2019-06-04 2023-01-17 Lab NINE, Inc. System and apparatus for non-invasive measurement of transcranial electrical signals, and method of calibrating and/or using same for various applications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
JP3367581B2 (ja) * 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
JP5026083B2 (ja) * 2003-10-31 2012-09-12 クロンズ ホールディングズ カンパニー リミテッド 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法

Also Published As

Publication number Publication date
EP1942940A2 (en) 2008-07-16
ZA200800981B (en) 2009-04-29
US20080253996A1 (en) 2008-10-16
AR058173A1 (es) 2008-01-23
WO2007051785A2 (en) 2007-05-10
JP2009513689A (ja) 2009-04-02
BRPI0617823A2 (pt) 2011-08-09
EA200801244A1 (ru) 2009-02-27
CA2617598A1 (en) 2007-05-10
AU2006310577B2 (en) 2012-04-19
CN101300031A (zh) 2008-11-05
EA015716B1 (ru) 2011-10-31
NZ565639A (en) 2012-03-30
WO2007051785A3 (en) 2007-09-07
AU2006310577A1 (en) 2007-05-10
KR20080060226A (ko) 2008-07-01

Similar Documents

Publication Publication Date Title
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
UA98629C2 (ru) Соединения и способ модуляции киназ
DE602006016449D1 (ru)
TW200612926A (en) Compounds and compositions as ppar modulators
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2007022470A3 (en) Methods and compositions for treating neurological disease
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
MY147247A (en) Organic compounds and their uses
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
TNSN06381A1 (en) Compounds and compositions as ppar modulators
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA85187C2 (en) 2-aminobenzoyl derivatives
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии
WO2008028888A3 (en) Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
ECSP088411A (es) Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas.
WO2005023288A8 (en) Treatment of fibrotic disease